Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO https://lnkd.in/dRW-raGf
TREOS BIO LIMITED
Biotechnology Research
Peptide Immunotherapy Digitally Matched to Patient Genetics
About us
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.
- Website
-
http://treosbio.com
External link for TREOS BIO LIMITED
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- LONDON
- Type
- Privately Held
- Specialties
- Immuno-oncology
Locations
-
Primary
Get directions
The Harley Building, 79 New Cavendish Street
LONDON, W1W 6XB, GB
Employees at TREOS BIO LIMITED
Updates
-
At American Society of Clinical Oncology (ASCO) 2024, TREOS BIO LIMITED Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer. PolyPEPI1018 is the first cancer vaccine to demonstrate promising results when combined with a PD-(L)1 inhibitor in late-stage microsatellite stable colorectal cancer (MSS CRC), a form of cancer —representing 96% of all metastatic CRC — historically resistant to checkpoint inhibitor immunotherapy. We sincerely thank all patients and their families and the investigators and site staff members at Mayo Clinic led by Joleen Hubbard. We are also grateful to Roche for the great collaboration in this important study. https://lnkd.in/dRW-raGf
-
-
Treos Bio will be attending Jefferies Global Healthcare Conference. We have overcome critical challenges of immunotherapies by using our proprietary, computational platform based on HLA genetics, tumor profiles, and clinical outcomes from thousands of real subjects. Our lead investigational therapy, PolyPEPI1018, is an off-the-shelf immunotherapy that has now been evaluated through three clinical trials at the Mayo Clinic in several advanced stage microsatellite stable metastatic colorectal cancer settings. It has consistently demonstrated a unique ability to turn cold tumors hot and shown strong immunogenicity, tumor-infiltrating lymphocyte induction, and overall response rates. If you are interested in learning more, contact Gabor Illes to schedule a meeting.
-
-
Going to 2024 ASCO? Members of Treos Bio's management team Christopher Gallen, Gabor Illes, Eniko Toke, PhD, and Hagop Youssoufian will be there discussing the latest results on its off-the-shelf, peptide immunotherapy. Let us know if you’d like to set up a meeting. https://lnkd.in/gQn9ki2a
-